| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.0075 | 0.9 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.9 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.9 |